Live attenuated vaccines in patients receiving immunosuppressive agents.
Cellular immunodeficiency
Contraindication
Immunosuppressive agent
Infectious disease
Live attenuated vaccine
Steroid
Varicella
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
14
01
2023
accepted:
27
03
2023
revised:
22
03
2023
medline:
23
10
2023
pubmed:
20
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
The use of live attenuated vaccines in patients with immunosuppressive agents is contraindicated in package inserts and guidelines in Japan and other countries. However, patients receiving immunosuppressants have a high risk of infectious disease becoming severe, and the necessity to prevent infectious disease is high. To date, 2,091 vaccinations have been reported in 25 reports of live attenuated vaccines in people receiving immunosuppressants. Twenty-three patients (1.1%) became infected with the virus strain used in the vaccine, which was varicella virus in 21 patients. No reports have described life-threatening complications. A prospective study at the National Center for Child Health and Development conducted under certain immunological conditions (CD4 cell count ≥ 500/mm
Identifiants
pubmed: 37076756
doi: 10.1007/s00467-023-05969-z
pii: 10.1007/s00467-023-05969-z
pmc: PMC10115603
doi:
Substances chimiques
Immunosuppressive Agents
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3889-3900Informations de copyright
© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases Society of America (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:e44–e100. https://doi.org/10.1093/cid/cit684
doi: 10.1093/cid/cit684
pubmed: 24311479
Lynfield R, Herrin JT, Rubin RH (1992) Varicella in pediatric renal transplant recipients. Pediatrics 90:216–220
doi: 10.1542/peds.90.2.216
pubmed: 1322522
Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C (1997) Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 99:35–39. https://doi.org/10.1542/peds.99.1.35
doi: 10.1542/peds.99.1.35
pubmed: 8989334
Feldhoff CM, Balfour HH Jr, Simmons RL, Najarian JS, Mauer SM (1981) Varicella in children with renal transplants. J Pediatr 98:25–31. https://doi.org/10.1016/s0022-3476(81)80527-6
doi: 10.1016/s0022-3476(81)80527-6
pubmed: 7005416
Kashtan CE, Cook M, Chavers BM, Mauer SM, Nevins TE (1997) Outcome of varicella in 66 pediatric renal transplant recipients. J Pediatr 131:874–877. https://doi.org/10.1016/s0022-3476(97)70036-2
doi: 10.1016/s0022-3476(97)70036-2
pubmed: 9427893
Furth SL, Sullivan EK, Neu AM, Tejani A, Fivush BA (1997) Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1:37–42
pubmed: 10084785
McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC Jr (1989) Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 83:256–261
doi: 10.1542/peds.83.2.256
pubmed: 2536479
Pacini-Edelstein SJ, Mehra M, Ament ME, Vargas JH, Martin MG, McDiarmid SV (2003) Varicella in pediatric liver transplant patients: a retrospective analysis of treatment and outcome. J Pediatr Gastroenterol Nutr 37:183–186. https://doi.org/10.1097/00005176-200308000-00018
doi: 10.1097/00005176-200308000-00018
pubmed: 12883306
Dodd DA, Burger J, Edwards KM, Dummer JS (2001) Varicella in a pediatric heart transplant population on nonsteroid maintenance immunosuppression. Pediatrics 108:E80. https://doi.org/10.1542/peds.108.5.e80
doi: 10.1542/peds.108.5.e80
pubmed: 11694664
Morgan ER, Smalley LA (1983) Varicella in immunocompromised children. Incidence of abdominal pain and organ involvement. Am J Dis Child 137:883–885. https://doi.org/10.1001/archpedi.1983.02140350057014
doi: 10.1001/archpedi.1983.02140350057014
pubmed: 6613954
Feldman S, Hughes WT, Daniel CB (1975) Varicella in children with cancer: Seventy-seven cases. Pediatrics 56:388–397
doi: 10.1542/peds.56.3.388
pubmed: 1088828
Bradley JR, Wreghitt TG, Evans DB (1987) Varicella in adult renal transplant recipients. Nephrol Dial Transplant 1:242–245
pubmed: 3110682
Errasti P, Alvarez ML, Gomez G, Lavilla FJ, Garcia N, Ballester B, García I, Purroy A (1999) Varicella in four adult renal transplant recipients. Transplant Proc 31:2341–2342. https://doi.org/10.1016/s0041-1345(99)00369-3
doi: 10.1016/s0041-1345(99)00369-3
pubmed: 10500608
Heininger U, Seward JF (2006) Varicella. Lancet 368:1365–1376. https://doi.org/10.1016/S0140-6736(06)69561-5
Kaplan LJ, Daum RS, Smaron M, McCarthy CA (1992) Severe measles in immunocompromised patients. JAMA 267:1237–1241
doi: 10.1001/jama.1992.03480090085032
pubmed: 1538561
Hughes I, Jenney ME, Newton RW, Morris DJ, Klapper PE (1993) Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia. Arch Dis Child 68:775–778. https://doi.org/10.1136/adc.68.6.775
doi: 10.1136/adc.68.6.775
pubmed: 8333771
pmcid: 1029373
Kernahan J, McQuillin J, Craft AW (1987) Measles in children who have malignant disease. Br Med J (Clin Res Ed) 295:15–18. https://doi.org/10.1136/bmj.295.6589.15
doi: 10.1136/bmj.295.6589.15
pubmed: 3113596
Gray MM, Hann IM, Glass S, Eden OB, Jones PM, Stevens RF (1987) Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective review. Br Med J (Clin Res Ed) 295:19–22. https://doi.org/10.1136/bmj.295.6589.19
doi: 10.1136/bmj.295.6589.19
pubmed: 3113597
Nakano T, Shimono Y, Sugiyama K, Nishihara H, Higashigawa M, Komada Y, Ito M, Sakurai M, Yoshida A, Kitamura K, Ihara T, Kamiya H, Hamazaki M, Sata T (1996) Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 38:212–217. https://doi.org/10.1111/j.1442-200x.1996.tb03472.x
doi: 10.1111/j.1442-200x.1996.tb03472.x
pubmed: 8741308
Bakshi N, Lawson J, Hanson R, Ames C, Vinters HV (1996) Fatal mumps meningoencephalitis in a child with severe combined immunodeficiency after bone marrow transplantation. J Child Neurol 11:159–162. https://doi.org/10.1177/088307389601100218
doi: 10.1177/088307389601100218
pubmed: 8881994
Rand EB, McCarthy CA, Whitington PF (1993) Measles vaccination after orthotopic liver transplantation. J Pediatr 123:87–89. https://doi.org/10.1016/s0022-3476(05)81545-8
doi: 10.1016/s0022-3476(05)81545-8
pubmed: 8320632
Zamora I, Simon JM, Da Silva ME, Piqueras AI (1994) Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 8:190–192. https://doi.org/10.1007/BF00865476
doi: 10.1007/BF00865476
pubmed: 8018498
Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, Saito M, Narita M, Kawarasaki H, Igarashi T, Hashizume K, Iwata T (2002) Efficacy and safety of immunization for pre- and post- liver transplant children. Transplantation 74:543–550. https://doi.org/10.1097/00007890-200208270-00020
doi: 10.1097/00007890-200208270-00020
pubmed: 12352917
Levitsky J, Te HS, Faust TW, Cohen SM (2002) Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant 2:880–882. https://doi.org/10.1034/j.1600-6143.2002.20912.x
doi: 10.1034/j.1600-6143.2002.20912.x
pubmed: 12392296
Chaves TdoS, Lopes MH, de Souza VA, de Souza Dos Santos S, Pereira LM, Reis AD, David-Neto E (2005) Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 9:192–196. https://doi.org/10.1111/j.1399-3046.2005.00279.x
doi: 10.1111/j.1399-3046.2005.00279.x
pubmed: 15787792
Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, Kochanowicz S, Seipel KR, Levin MJ (2006) Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 6:565–658. https://doi.org/10.1111/j.1600-6143.2005.01210.x
doi: 10.1111/j.1600-6143.2005.01210.x
pubmed: 16468967
Khan S, Erlichman J, Rand EB (2006) Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 10:78–82. https://doi.org/10.1111/j.1399-3046.2005.00403.x
doi: 10.1111/j.1399-3046.2005.00403.x
pubmed: 16499592
Kraft JN, Shaw JC (2006) Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol 142:943–945. https://doi.org/10.1001/archderm.142.7.943
doi: 10.1001/archderm.142.7.943
pubmed: 16847227
Lu Y, Bousvaros A (2010) Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 50:562–565. https://doi.org/10.1097/MPG.0b013e3181bab351
doi: 10.1097/MPG.0b013e3181bab351
pubmed: 20639716
pmcid: 3955715
Posfay-Barbe KM, Pittet LF, Sottas C, Grillet S, Wildhaber BE, Rodriguez M, Kaiser L, Belli DC, McLin VA, Siegrist CA (2012) Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant 12:2974–2985. https://doi.org/10.1111/j.1600-6143.2012.04273.x
doi: 10.1111/j.1600-6143.2012.04273.x
pubmed: 22994936
Azevedo LS, Lasmar EP, Contieri FL, Boin I, Percegona L, Saber LT, Selistre LS, Netto MV, Moreira MC, Carvalho RM, Bruno RM, Ferreira TC, David-Neto E (2012) Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis 14:237–241. https://doi.org/10.1111/j.1399-3062.2011.00686.x
doi: 10.1111/j.1399-3062.2011.00686.x
pubmed: 22093046
Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, Marr KA, Hecox D, Amanna IJ (2013) Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG. Transplantation 95:e59–e61. https://doi.org/10.1097/TP.0b013e31828c6d9e
doi: 10.1097/TP.0b013e31828c6d9e
pubmed: 23648410
pmcid: 3647227
Kawano Y, Suzuki M, Kawada J, Kimura H, Kamei H, Ohnishi Y, Ono Y, Uchida H, Ogura Y, Ito Y (2015) Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine 33:1440–1445. https://doi.org/10.1016/j.vaccine.2015.01.075
doi: 10.1016/j.vaccine.2015.01.075
pubmed: 25665961
Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T (2008) Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine 26:6859–6863
doi: 10.1016/j.vaccine.2008.09.076
pubmed: 18930096
Shinjoh M, Hoshino K, Takahashi T, Nakayama T (2015) Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine 33:701–707. https://doi.org/10.1016/j.vaccine.2008.09.076
doi: 10.1016/j.vaccine.2008.09.076
pubmed: 25510391
Kamei K, Miyairi I, Ishikura K, Ogura M, Shoji K, Funaki T, Ito R, Arai K, Abe J, Kawai T, Onodera M, Ito S (2018) Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents. J Pediatr 196:217–222. https://doi.org/10.1016/j.jpeds
doi: 10.1016/j.jpeds
pubmed: 29499990
Verolet CM, Pittet LF, Wildhaber BE, McLin VA, Rodriguez M, Grillet S, Siegrist CA, Posfay-Barbe KM (2019) Long-term seroprotection of varicella-zoster immunization in pediatric liver transplant recipients. Transplantation 103:e355–e364. https://doi.org/10.1097/TP.0000000000002866
doi: 10.1097/TP.0000000000002866
pubmed: 31335765
Pittet LF, Verolet CM, McLin VA, Wildhaber BE, Rodriguez M, Cherpillod P, Kaiser L, Siegrist CA, Posfay-Barbe KM (2019) Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. Am J Transplant 19:844–854. https://doi.org/10.1111/ajt.15101
doi: 10.1111/ajt.15101
pubmed: 30171797
Ortiz-Brizuela E, Leal-Vega F, Cuellar-Rodríguez J, Bobadilla-Del-Valle M, Ponce-de-León A (2019) Vaccine-derived varicella zoster infection in a kidney transplant recipient after zoster vaccine live administration. Vaccine 37:3576–3579. https://doi.org/10.1016/j.vaccine.2019.05.017
doi: 10.1016/j.vaccine.2019.05.017
pubmed: 31109718
de Sousa MV, Zollner RL, Stucchi RSB, Boin IFSF, de Ataide EC, Mazzali M (2019) Yellow fever disease in a renal transplant recipient: Case report and literature review. Transpl Infect Dis 21:e13151. https://doi.org/10.1111/tid.13151
doi: 10.1111/tid.13151
pubmed: 31344763
Bobrowski AE, Muller WJ (2020) Varicella infection following vaccination in a pediatric kidney transplant recipient. Pediatr Transplant 24:e13667. https://doi.org/10.1111/petr.13667
doi: 10.1111/petr.13667
pubmed: 32068320
Kamei K, Miyairi I, Ishikura K, Ogura M, Shoji K, Arai K, Ito R, Kawai T, Ito S (2020) Prospective study of live attenuated vaccines for patients receiving immunosuppressive agents. PLoS One 15:e0240217. https://doi.org/10.1371/journal.pone.0240217
doi: 10.1371/journal.pone.0240217
pubmed: 33002085
pmcid: 7529194
Funaki T, Shoji K, Fukuda A, Sakamoto S, Kasahara M, Miyairi I (2021) Safety of LAVs administered after pediatric LT. Pediatr Transplant 25:e13937. https://doi.org/10.1111/petr.13937
doi: 10.1111/petr.13937
pubmed: 33314516
Kamei K, Miyairi I, Shoji K, Arai K, Kawai T, Ogura M, Ishikura K, Sako M, Nakamura H (2021) Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan. Eur J Pediatr 180:1847–1854. https://doi.org/10.1007/s00431-021-03927-1
doi: 10.1007/s00431-021-03927-1
pubmed: 33523302
Newman AM, Posch LC, Gianchetti L, Rand EB, Mohammad S, Downes KJ, Muller WJ (2022) Live virus vaccination following pediatric liver transplantation: Outcomes from two academic children’s hospitals. Am J Transplant 22:1201–1212. https://doi.org/10.1111/ajt.16937
doi: 10.1111/ajt.16937
pubmed: 34967134
Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011) Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118:6769–6771. https://doi.org/10.1182/blood-2011-08-372649
doi: 10.1182/blood-2011-08-372649
pubmed: 22058114
Avouac J, Miceli-Richard C, Combier A, Steelandt A, Fogel O, Mariaggi AA, Meritet JF, Rozenberg F, Molto A, Allanore Y (2022) Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients. Rheumatology (Oxford) 61(SI2):SI163–SI168. https://doi.org/10.1093/rheumatology/keab815
doi: 10.1093/rheumatology/keab815
pubmed: 34726701
Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, Kotsch K, Chen Y, Claußnitzer A, Haibel H, Proft F, Guerra G, Durek P, Heinrich F, Ferreira-Gomes M, Burmester GR, Radbruch A, Mashreghi MF, Lino AC, Dörner T (2022) B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. Arthritis Rheumatol 74:934–947. https://doi.org/10.1002/art.42060
doi: 10.1002/art.42060
pubmed: 34962360
pmcid: 9011692